WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma

被引：0
|
作者：
Nicholas Coupe
Lina Guo
Esther Bridges
Leticia Campo
Olivia Espinosa
Richard Colling
Andrea Marshall
Ashwin Nandakumar
Ruud van Stiphout
Francesca M. Buffa
Pippa G. Corrie
Mark R. Middleton
Valentine M. Macaulay
机构：
[1] University of Oxford,Department of Oncology
[2] Oxford University Hospitals NHS Foundation Trust,Department of Oncology, Oxford Cancer and Haematology Centre
[3] Churchill Hospital,Department of Cellular Pathology
[4] Oxford University Hospitals NHS Foundation Trust,Warwick Clinical Trials Unit, Division of Health Sciences
[5] John Radcliffe Hospital,Nuffield Department of Surgical Sciences
[6] University of Warwick,Department of Oncology
[7] University of Oxford,undefined
[8] Cambridge University Hospitals NHS Foundation Trust,undefined
[9] Addenbrooke’s Hospital,undefined
来源：
Cellular Oncology | 2023年 / 46卷
关键词：
Melanoma; BRAF; Bevacizumab; ROR2; WNT5A;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：391 / 407
页数：16
相关论文
共 50 条
  • [31] The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells
    Yuan, Yuan
    Niu, Chang Chun
    Deng, Gang
    Li, Zhao Quan
    Pan, Jing
    Zhao, Chen
    Yang, Zong Lin
    Si, Wei Ke
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2011, 27 (01) : 63 - 69
  • [32] Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder
    Wu, Zheng-Chun
    Xiong, Li
    Wang, Ling-Xiang
    Miao, Xiong-Ying
    Liu, Zi-Ru
    Li, Dai-Qiang
    Zou, Qiong
    Liu, Kui-Jie
    Zhao, Hua
    Yang, Zhu-Lin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (14) : 2601 - 2612
  • [33] Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder
    Zheng-Chun Wu
    Li Xiong
    Ling-Xiang Wang
    Xiong-Ying Miao
    Zi-Ru Liu
    Dai-Qiang Li
    Qiong Zou
    Kui-Jie Liu
    Hua Zhao
    Zhu-Lin Yang
    World Journal of Gastroenterology, 2017, (14) : 2601 - 2612
  • [34] Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling
    Yadav, Vikas
    Jobe, Njainday
    Satapathy, Shakti Ranjan
    Mohapatra, Purusottam
    Andersson, Tommy
    CANCERS, 2022, 14 (24)
  • [35] Protocatechuic aldehyde sensitizes BRAF-mutant melanoma cells to temozolomide through inducing FANCD2 degradation
    Yang, Jie
    Zeng, Xin
    Pei, Junxia
    Su, Zhou
    Liu, Qi
    Zhang, Yamei
    Yang, Yixi
    Li, Rui
    Zhou, Fei
    Deng, Yu
    MEDICAL ONCOLOGY, 2025, 42 (02)
  • [36] Wnt5a/Ror2 promotes vascular smooth muscle cells proliferation via activating PKC
    Shi, Yaning
    Li, Hongfang
    Gu, Jia
    Gong, Yongzhen
    Xie, Xuejiao
    Liao, Duanfang
    Qin, Li
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2022, 60 (03) : 271 - 279
  • [37] Structure and function of the ROR2 cysteine-rich domain in vertebrate noncanonical WNT5A signaling
    Griffiths, Samuel C.
    Tan, Jia
    Wagner, Armin
    Blazer, Levi L.
    Adams, Jarrett J.
    Srinivasan, Srisathya
    Moghisaei, Shayan
    Sidhu, Sachdev S.
    Siebold, Christian
    Ho, Hsin-Yi Henry
    ELIFE, 2024, 13
  • [38] Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma
    Li, Weisong
    Zheng, Chao
    Xu, Xi
    Xia, Yujie
    Zhang, Kai
    Huang, Ao
    Zhang, Xinyu
    Zheng, Yong
    Chen, Guofang
    Zhang, Shuyong
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2024, 29 (01)
  • [39] FAM129B-dependent activation of NRF2 promotes an invasive phenotype in BRAF mutant melanoma cells
    Schmidlin, Cody J.
    Tian, Wang
    Dodson, Matthew
    Chapman, Eli
    Zhang, Donna D.
    MOLECULAR CARCINOGENESIS, 2021, 60 (05) : 331 - 341
  • [40] High expression levels of Wnt5a and Ror2 in laryngeal squamous cell carcinoma are associated with poor prognosis
    Zhang, Wei
    Yan, Yongbing
    Gu, Miao
    Wang, Xudong
    Zhu, Huijun
    Zhang, Shu
    Wang, Wei
    ONCOLOGY LETTERS, 2017, 14 (02) : 2232 - 2238
12345